Xeris Biopharma (XERS) Stock: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$10.20
-0.66 (-6.08%)
âŧ
5d:
-1.07%
30d:
+13.97%
90d:
+24.24%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: XERS is fairly priced but lacks strong directional signals. At 11.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: XERS is fairly priced but lacks strong directional signals. At 11.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.42
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.47
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $10.20, which is considered slightly high relative to its 30-day fair value range of $8.55 to $10.57. From a valuation perspective, the stock is trading at a premium (Forward PE: 27.6) compared to its historical average (20.1). At these levels, the market is pricing in 11.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $9.73, while resistance sits at $11.41. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: XERS scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.86 (+26.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $9.73, while resistance sits at $11.41. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: XERS scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.86 (+26.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.55 -
$10.57
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
37.1%
All Signals
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.1%)
- BULLISH: Trading 26.1% below Wall St target ($12.86)
- NEUTRAL: Trading at premium valuation - market expects 11.1% growth which is achievable
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.55 -
$10.57
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.73
Resistance Level
$11.42
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.57
Wall Street Target
$12.86
(+26.1%)
Revenue Growth (YoY)
28.7%
Profit Margin
-5.1%
Valuation Premium vs History
+11.1% premium
PE vs Historical
27.6 vs 20.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.1%
(market-implied from PE analysis)
1-Year Target
$11.33
(+11%)
2-Year Target
$12.59
(+23%)
3-Year Target
$13.99
(+37%)
3-Yr Target (if PE normalizes)
(PE: 28â20)
PE COMPRESSION
$10.20
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 23, 2026 9:54 PM ET
Data refreshes hourly during market hours. Next update: 10:54 PM
Data refreshes hourly during market hours. Next update: 10:54 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 54 HOLD |